Your session is about to expire
← Back to Search
Telehealth Care-Coordination for Mental Illness (BHH Trial)
N/A
Waitlist Available
Led By George Unick
Research Sponsored by University of Maryland, Baltimore
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Prescribed psychiatric medications
Aged 18 to 80 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up two years prior to study enrollment to at least one year after study enrollment.
Awards & highlights
No Placebo-Only Group
Summary
This trial tests the Medherent platform, a telehealth service that helps people with serious mental illnesses manage their medications and health care. It targets those who often miss their medications and have poor health outcomes. The platform provides remote support to improve their health and reduce hospital visits.
Who is the study for?
This trial is for adults aged 18-80 with Serious Mental Illness (SMI) who are prescribed psychiatric medications and receive services from a participating community mental health agency. They must be willing to have the Medherent device in their residence, either as current users or new participants.
What is being tested?
The study tests the Medherent medication management platform along with additional telehealth care-coordination services aimed at improving health outcomes for individuals with SMI living in community settings.
What are the potential side effects?
Since this trial involves a telehealth service rather than a drug, traditional side effects aren't expected. However, there may be challenges like adapting to technology use and privacy concerns.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am taking medication for a mental health condition.
Select...
I am between 18 and 80 years old.
Select...
I am unable to understand and consent to the study.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ two years prior to study enrollment to at least one year after study enrollment.
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~two years prior to study enrollment to at least one year after study enrollment.
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change in Health Service Costs
Consumer Satisfaction STAR-P
Diabetes control as reported hemoglobin A1c levels
+3 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
3Treatment groups
Experimental Treatment
Active Control
Group I: New MedherentExperimental Treatment1 Intervention
Group using Medherent Device with added interventional components.
Group II: Usual CareActive Control1 Intervention
Usual Care: no intervention elements.
Group III: Existing MedherentActive Control1 Intervention
Group using the Medherent Device with no added intervention components.
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for mental disorders include pharmacological interventions and telehealth services. Medications like antipsychotics, antidepressants, and mood stabilizers work by adjusting neurotransmitter levels in the brain to stabilize mood, reduce psychotic symptoms, and alleviate depression.
Telehealth interventions, such as those studied in the Medherent platform, enhance medication adherence and health outcomes by providing remote access to healthcare services, continuous monitoring, and timely interventions. This approach is crucial for patients with serious mental illnesses who face barriers to in-person care, offering a more flexible and accessible way to manage their conditions and improve overall health outcomes.
Emerging Needs and Viability of Telepsychiatry During and Post COVID-19 Era: A Literature Review.Collaborative Care for Psychiatric Disorders in Older Adults: A Systematic Review.
Emerging Needs and Viability of Telepsychiatry During and Post COVID-19 Era: A Literature Review.Collaborative Care for Psychiatric Disorders in Older Adults: A Systematic Review.
Find a Location
Who is running the clinical trial?
University of Maryland, BaltimoreLead Sponsor
716 Previous Clinical Trials
380,809 Total Patients Enrolled
George UnickPrincipal InvestigatorUniversity of Maryland
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am taking medication for a mental health condition.I am between 18 and 80 years old.I am unable to understand and consent to the study.
Research Study Groups:
This trial has the following groups:- Group 1: Usual Care
- Group 2: Existing Medherent
- Group 3: New Medherent
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.